The Yanomami Indigenous people, in Roraima, became the first patients in Brazil to receive tafenoquine and point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing for P. vivax malaria, following the decision of the government to adopt the use of these new health technology innovations